The one and perhaps only saving grace for these pump newcomers and Insulet, are companies like Sanofi-Aventis (NYSE:SNY), Novo Nordisk (NYSE:NVO) and possibly Lilly (NYSE:LLY) who see pumps not necessarily as a profit center but rather as a tool to sell more of their core insulin products. Yet even if this is true with so many new entrants into this space it has become a buyers' market. The days of huge multiples are long gone as any potential suitor can basically play these companies off one another. While they all will beg to differ, none of their products stand out as really that much better than systems that are already on the market.